Battle Over Patents And Drug Pricing Engulfs FDA And USPTO

President Biden and Congress are pressuring the agencies to change patent policies so brand manufacturers cannot delay generic and biosimilar competition to keep monopoly prices. Timeline shows how they have responded to these demands.  

FDA_PTO
USPTO and FDA face pressure to take action on patents and drug pricing • Source: Nielsen Hobbs; In Vivo | Shutterstock images

More from Market Access

More from In Vivo